- Home
- ANVS vs HOWL Comparison
ANVS vs HOWL Comparison
Compare ANVS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- HOWL
- Stock Information
- Founded
- ANVS 2008
- HOWL 2017
- Country
- ANVS United States
- HOWL United States
- Employees
- ANVS N/A
- HOWL N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- HOWL Health Care
- Exchange
- ANVS Nasdaq
- HOWL Nasdaq
- Market Cap
- ANVS 55.5M
- HOWL 47.1M
- IPO Year
- ANVS 2020
- HOWL 2021
- Fundamental
- Price
- ANVS $2.34
- HOWL $1.33
- Analyst Decision
- ANVS Strong Buy
- HOWL Strong Buy
- Analyst Count
- ANVS 4
- HOWL 5
- Target Price
- ANVS $17.33
- HOWL $7.20
- AVG Volume (30 Days)
- ANVS 231.9K
- HOWL 135.8K
- Earning Date
- ANVS 11-07-2025
- HOWL 11-06-2025
- Dividend Yield
- ANVS N/A
- HOWL N/A
- EPS Growth
- ANVS N/A
- HOWL N/A
- EPS
- ANVS N/A
- HOWL N/A
- Revenue
- ANVS N/A
- HOWL N/A
- Revenue This Year
- ANVS N/A
- HOWL N/A
- Revenue Next Year
- ANVS N/A
- HOWL N/A
- P/E Ratio
- ANVS N/A
- HOWL N/A
- Revenue Growth
- ANVS N/A
- HOWL N/A
- 52 Week Low
- ANVS $1.11
- HOWL $0.60
- 52 Week High
- ANVS $10.54
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- ANVS 43.00
- HOWL 52.75
- Support Level
- ANVS $2.21
- HOWL $1.29
- Resistance Level
- ANVS $2.51
- HOWL $1.40
- Average True Range (ATR)
- ANVS 0.13
- HOWL 0.07
- MACD
- ANVS -0.01
- HOWL 0.00
- Stochastic Oscillator
- ANVS 25.35
- HOWL 61.90
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.